43
Participants
Start Date
May 31, 2014
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
A(H5N1) inactivated influenza vaccine (IIV)
Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.
A(H5N2) live attenuated influenza vaccine (LAIV)
Two doses of A(H5N2) live attenuated influenza vaccine (LAIV) administered 28 days apart, approximately 1.5 years prior to receiving A(H5N1) IIV
Research Institute of Influenza, Saint Petersburg
Institute of Experimental Medicine, Russia
OTHER
Research Institute of Influenza, Russia
OTHER
PATH
OTHER